Olema Oncology
Richard Hernandez joined Olema in August 2022 as Vice President of Clinical Development Operations. Mr. Hernandez is a clinical development operations professional with over 25 years of pharmaceutical/biotech industry experience working at a clinical site, a contract research organization, and multiple sponsor companies. Most recently, Mr. Hernandez served as Vice President of Clinical Operations at Genocea leading the Clinical Operations team on the development of two immuno-oncology programs. Prior to that, he held various clinical operations leadership roles with increased responsibilities developing and implementing clinical programs from pre-IND though post marketing at MedImmune, Vertex Pharmaceuticals, Biogen, and LFB USA. Mr. Hernandez earned his B.S. in biopsychology from the University of Michigan.
This person is not in any offices
Olema Oncology
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.